Positive high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) met the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced solid tumours in heavily pretreated patients.
Starfield, the latest RPG from Bethesda, a subsidiary of Microsoft Corp (NASDAQ: MSFT), is astonishing players with incredible attention to detail in the
Bionano has completed the early access program for the Stratys™ system and is now making it available in a full commercial release The Stratys instrument can enable up to a four-fold increase in raw data